Sarepta Therapeutics, Inc. (SRPT)

Sarepta Therapeutics, Inc. (SRPT) is a healthcare company (biotechnology) based in the United States. The share price is $14.93, down 1.35% on the day, which values the company at $1.6B. Price as of 17 Nov 2026, 17:36 UTC, from Yahoo Finance.

Key facts

Share price
$14.93−1.35% today
Market value
$1.6B
P/E ratio
746.3×last 12 months
Forward P/E
10.1×
Funk Score
50/100
Against its own history
Well below its usual priceusual price $268.74
200-week average
$78.2881% below
Sector
Healthcare

Figures as of . Prices from Yahoo Finance (may be delayed); statements from company filings with the SEC and Yahoo Finance. Estimates, not advice.

Sarepta Therapeutics, Inc. in more detail

SRPT trades at 746.3× its last twelve months' earnings, 10.1× next year's expected earnings, 0.8× sales. Measured against its own history, the price is 94% below what its usual multiples would imply ($268.74) — well below its usual price. It sits 81% below its 200-week average of $78.28.

Over the last five fiscal years Sarepta Therapeutics, Inc. has compounded revenue 37.0% a year. Its Funk Score is 50 out of 100 (financial strength 3.0, profitability 2.2, growth 10.0, value 5.0, each out of 10).

In its favour: Five straight years of revenue growth. Worth checking: Altman Z in the distress zone; Thin interest cover.

Sarepta Therapeutics, Inc. (SRPT): questions and answers

What is SRPT's P/E ratio?

Sarepta Therapeutics, Inc. trades at 746.3× its last twelve months' earnings and 10.1× next year's expected earnings.

What is SRPT's PEG ratio?

Sarepta Therapeutics, Inc.'s PEG ratio is -0.09 — its P/E divided by its expected earnings growth. Around 1 is the classic sign of a price that matches the growth; well above it means the growth is being paid for in advance.

What is Sarepta Therapeutics, Inc.'s market cap?

Sarepta Therapeutics, Inc. is valued at $1.6B at a share price of $14.93.

Is SRPT overvalued or undervalued?

Against its own history, SRPT is well below its usual price: the price is 94% below the $268.74 implied by the median multiples it has traded at (price / sales, price / book). That compares the stock with its past; it does not say whether the business now deserves a higher or lower multiple.

Is SRPT above its 200-week moving average?

No. SRPT is 80.9% below its 200-week average of $78.28. Long-term investors watch that line because strong companies rarely trade below it for long.

How fast is Sarepta Therapeutics, Inc. growing?

Over the last five fiscal years Sarepta Therapeutics, Inc.'s revenue grew 37.0% a year; over ten years revenue grew 111.1% a year.

Cite this page

Funkfolio, “Sarepta Therapeutics, Inc. (SRPT) stock: price, valuation and fundamentals”, data as of 17 November 2026. https://funkfolio.com/stock/SRPT

Underlying data: Yahoo Finance; company filings with the SEC.